China Universal Asset Management Co., Ltd. Seagen Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$191.51 - $216.16 $545,995 - $616,272	2,851 Added 106.82%	5,520 $1.17 Million
Q3 2023 Oct 30, 2023	BUY	$191.51 - $216.16 $545,995 - $616,272	2,851 Added 106.82%	5,520 $1.17 Million
Q2 2023 May 21, 2024	BUY	$187.64 - $206.25 $15,386 - $16,912	82 Added 3.17%	2,669 $513,000
Q2 2023 Jul 27, 2023	BUY	$187.64 - $206.25 $15,386 - $16,912	82 Added 3.17%	2,669 $514,000
Q1 2023 May 21, 2024	BUY	$127.59 - $203.08 $89,440 - $142,359	701 Added 37.17%	2,587 $523,000
Q1 2023 Apr 27, 2023	BUY	$127.59 - $203.08 $89,440 - $142,359	701 Added 37.17%	2,587 $524,000
Q4 2022 May 21, 2024	BUY	$117.37 - $139.17 $221,359 - $262,474	1,886 New	1,886 $242,000
Q4 2022 Jan 31, 2023	BUY	$117.37 - $139.17 $18,661 - $22,128	159 Added 9.21%	1,886 $242,000
Q3 2022 Oct 21, 2022	BUY	$135.27 - $180.11 $233,611 - $311,049	1,727 New	1,727 $236,000

Others Institutions Holding SGEN

# of Institutions

Shares Held

1.26M

Call Options Held

23K

Put Options Held

55.2K

View Full List

About Seagen Inc.

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

More about SGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account